Immunotherapy in Sarcoma: Current Data and Promising Strategies.
Am Soc Clin Oncol Educ Book
; 44(3): e432234, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38781557
ABSTRACT
Traditionally sarcomas have been considered immunologically quiet tumours, with low tumour mutational burden (TMB) and an immunosuppressive tumour microenvironment (TME), consisting of decreased T-cell infiltration and elevated levels of H1F1α, macrophages and neutrophils.1,2 However, research has shown that a subset of sarcomas are immunologically 'hot' with either high TMB, PDL-1 expression, CD8+ T cells or presence of tertiary lymphoid structures (TLS) demonstrating sensitivity to immunotherapy.3,4 Here, we review the current evidence for immunotherapy use in bone sarcomas (BS) and soft tissue sarcomas (STS), with immune checkpoint inhibitors (ICI) and adoptive cellular therapies including engineered T-cell therapies, chimeric antigen receptor (CAR) T-cell therapies, tumour infiltrating lymphocytes (TILs) and cancer vaccines and biomarkers of response.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Microambiente Tumoral
/
Imunoterapia
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article